Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

1081. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.

Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. 2899772 1988 09 08 1988 09 08 2015 06 16 0140-6736 2 8607 1988 Aug 13 Lancet (London, England) Lancet Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second (...) International Study of Infarct Survival) Collaborative Group. 349-60 17,187 patients entering 417 hospitals up to 24 hours (median 5 hours) after the onset of suspected acute myocardial infarction were randomised, with placebo control, between: (i) a 1-hour intravenous infusion of 1.5 MU of streptokinase; (ii) one month of 160 mg/day enteric-coated aspirin; (iii) both active treatments; or (iv) neither. Streptokinase alone and aspirin alone each produced a highly significant reduction in 5-week vascular

Lancet1988

1082. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group.

The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. 2899840 1988 08 31 1988 08 31 2013 11 21 0028-4793 319 7 1988 Aug 18 The New England journal of medicine N. Engl. J. Med. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. 385-92 We studied the effect of diltiazem on mortality and reinfarction in 2466 (...) in the minority of patients with left ventricular dysfunction. eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 EE92BBP03H Diltiazem AIM IM Aged Clinical Trials as Topic Diltiazem therapeutic use Electrocardiography Female Follow-Up Studies Humans Male Middle Aged Myocardial Infarction drug therapy mortality physiopathology Pulmonary Edema complications Recurrence Stroke Volume 1988 8 18 1988 8 18 0 1 1988 8 18 0 0

NEJM1988

1083. Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials.

Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. 3398199 1988 09 06 1988 09 06 2016 10 17 0098-7484 260 7 1988 Aug 19 JAMA JAMA Cardiac rehabilitation after myocardial infarction. Combined experience of randomized clinical trials. 945-50 Randomized clinical trials of cardiac rehabilitation following myocardial infarction have typically demonstrated a lower mortality in treated patients, but with a statistically significant reduction in only (...) one trial. To overcome the problem of not being able to detect small but clinically important benefits in mortality in randomized clinical trials of exercise and risk factor rehabilitation after myocardial infarction with small numbers of patients, we carried out a meta-analysis on the combined results of ten randomized clinical trials that included 4347 patients (control, 2145 patients; rehabilitation, 2202 patients). The pooled odds ratios of 0.76 (95% confidence intervals, 0.63 to 0.92) for all

JAMA1988

1084. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials.

Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. 3047448 1988 10 17 1988 10 17 2016 10 17 0098-7484 260 13 1988 Oct 07 JAMA JAMA Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials. 1910-6 The effects of prophylactic lidocaine hydrochloride on early ventricular fibrillation and death in patients with suspected acute (...) myocardial infarction were investigated in an overview of 14 randomized trials. During follow-up intervals of one to four hours in the trials of intramuscular lidocaine infusion (6961 patients) and 24 to 48 hours in the trials of intravenous lidocaine injection (2194 patients), a total of 103 cases of ventricular fibrillation and 137 deaths were recorded. Overall, allocation to lidocaine was associated with a reduction in the odds of ventricular fibrillation of about one third, with a 95% confidence interval

JAMA1988

1085. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction.

Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. 2893080 1988 03 07 1988 03 07 2015 06 16 0140-6736 1 8580 1988 Feb 06 Lancet (London, England) Lancet Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. 255-9 In a randomised, double-blind trial 60 patients with left ventricular dysfunction (ejection fraction less than 45%) but without clinical evidence of heart failure 1 week after Q wave (...) myocardial infarction were given captopril 25 mg thrice a day, frusemide 40 mg daily, or placebo. Left ventricular volumes were measured at baseline and at 1, 3, 6, 9, and 12 months with cross-sectional echocardiography and Simpson's rule analysis of standardised apical views. The captopril group showed no significant change in left ventricular end-diastolic volume index but left ventricular end-systolic volume index was significantly reduced and stroke volume index and ejection fraction were significantly

Lancet1988

1086. Early return to work after uncomplicated myocardial infarction. Results of a randomized trial.

Early return to work after uncomplicated myocardial infarction. Results of a randomized trial. 3385897 1988 07 29 1988 07 29 2016 10 17 0098-7484 260 2 1988 Jul 08 JAMA JAMA Early return to work after uncomplicated myocardial infarction. Results of a randomized trial. 214-20 To determine if an occupational work evaluation could shorten the time to return to work, 201 employed men aged 49 +/- 7 years who were recovering from uncomplicated myocardial infarction were randomized to usual care (n (...) = 102) or to an occupational work evaluation (n = 99). The occupational work evaluation consisted of a symptom-limited treadmill test performed 23 +/- 3 days after myocardial infarction and a formal recommendation to the patient and primary physician that the patient return to work within the next two weeks. The groups did not differ in age, medical status, comorbid disease, occupation type, or years on the job. At six months, 92% of patients receiving the intervention and 88% of patients receiving

JAMA1988

1087. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction.

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. 2967917 1988 07 25 1988 07 25 2013 11 21 0028-4793 319 2 1988 Jul 14 The New England journal of medicine N. Engl. J. Med. Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. 80-6 We conducted a double-blind, placebo-controlled trial to determine whether ventricular dilatation continues during the late convalescent phase after myocardial infarction (...) and whether therapy with captopril alters this process. Fifty-nine patients with a first anterior myocardial infarction and a radionuclide ejection fraction of 45 percent or less underwent cardiac catheterization 11 to 31 days after infarction, when they were not in overt congestive heart failure. They were randomly assigned to placebo or captopril and were followed for one year. A repeat catheterization was performed to evaluate interval changes in hemodynamic function and left ventricular volume. Thirty

NEJM1988

1088. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). 2900919 1988 10 05 1988 10 05 2016 11 23 0140-6736 2 8610 1988 Sep 03 Lancet (London, England) Lancet Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). 525-30 13,318 patients admitted to fifty-two coronary care units with suspected acute (...) myocardial infarction were considered for inclusion in a double-blind study comparing recombinant tissue-type plasminogen activator (rt-PA) 100 mg plus heparin with placebo plus heparin. 8307 (62%) were excluded, mainly because their symptoms had begun more than 5 h previously, but all excluded patients were followed up at least until hospital discharge. 2516 patients were randomly allocated to rt-PA and 2495 to placebo. At one month the overall case fatality rates were 7.2% and 9.8%, respectively, a relative

Lancet1988

1089. Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group.

Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative Group. 2895838 1988 05 26 1988 05 26 2016 11 23 0140-6736 1 8591 1988 Apr 23 Lancet (London, England) Lancet Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. ISIS-1 (First International Study of Infarct Survival) Collaborative (...) Group. 921-3 In a large randomised trial of early beta-blockade in acute myocardial infarction (ISIS-1), almost all the reduction in mortality associated with the use of atenolol occurred on the day of admission or on the subsequent day. To help determine the mechanisms that might be responsible for this retrospective observation, case notes were obtained for British, Irish, and Scandinavian patients who died during this early period. Of 217 early deaths adequate records were available for 193 (79

Lancet1988

1090. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion.

A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. 3281014 1988 05 12 1988 05 12 2007 11 15 0028-4793 318 17 1988 Apr 28 The New England journal of medicine N. Engl. J. Med. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. 1083-8 To evaluate the feasibility and cost savings of hospital discharge three days after acute myocardial infarction, we screened 507 (...) after a mean of 56.9 +/- 30.3 days (P = 0.054). The mean cumulative hospital and professional charges were $12,546 +/- 3,034 in the early-discharge group, as compared with $17,868 +/- 3,688 in the conventional-discharge group (P less than 0.0001). In carefully selected patients with uncomplicated myocardial infarction, hospital discharge after three days is feasible and leads to a substantial reduction in hospital charges. Before this strategy can be widely recommended, however, its safety must

NEJM1988

1091. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group.

Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. 2972848 1988 12 09 1988 12 09 2016 10 17 0098-7484 260 19 1988 Nov 18 JAMA JAMA Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group. 2849-58 The Thrombolysis in Myocardial Infarction II A Study investigated whether immediate (...) cardiac catheterization with percutaneous transluminal coronary angioplasty (PTCA), when appropriate, would confer an advantage over the same procedures performed 18 to 48 hours later. All patients were treated with intravenous recombinant tissue-type plasminogen activator within four hours of the onset of acute myocardial infarction. Percutaneous transluminal coronary angioplasty of the infarct-related artery was attempted in 72% of the 195 patients assigned to immediate PTCA; 84% of the attempts

JAMA1988

1092. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.

Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. 3146370 1989 03 23 1989 03 23 2013 11 21 0959-8138 297 6660 1988 Nov 26 BMJ (Clinical research ed.) BMJ Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. 1374-9 To assess effect of intravenous recombinant tissue type plasminogen activator on size of infarct, left ventricular (...) function, and survival in acute myocardial infarction. Double blind, randomised, placebo controlled prospective trial of patients with acute myocardial infarction within five hours after onset of symptoms. Twenty six referral centres participating in European cooperative study for recombinant tissue type plasminogen activator. Treatment group of 355 patients with acute myocardial infarction allocated to receive intravenous recombinant plasminogen activator. Controls comprised 366 similar patients

BMJ1988 Full Text: Link to full Text with Trip Pro

1093. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction.

Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. 2888018 1987 10 20 1987 10 20 2013 11 21 0028-4793 317 14 1987 Oct 01 The New England journal of medicine N. Engl. J. Med. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. 850-5 In a double-blind trial of streptokinase for acute myocardial infarction, 219 consecutive patients presenting with infarction within (...) with a first myocardial infarction results in improved left ventricular function and short-term survival. White H D HD Norris R M RM Brown M A MA Takayama M M Maslowski A A Bass N M NM Ormiston J A JA Whitlock T T eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't United States N Engl J Med 0255562 0028-4793 0 Adrenergic beta-Antagonists 9Y8NXQ24VQ Propranolol EC 3.4.- Streptokinase AIM IM Adrenergic beta-Antagonists administration & dosage Cineangiography

NEJM1987

1094. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty.

A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. 2960897 1988 01 20 1988 01 20 2007 11 15 0028-4793 317 26 1987 Dec 24 The New England journal of medicine N. Engl. J. Med. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. 1613-8 Patients presenting within four hours of the onset (...) of acute myocardial infarction were randomly assigned to receive 80 to 100 mg of recombinant human-tissue plasminogen activator (t-PA) intravenously over a period of three hours (n = 72) or placebo (n = 66). Administration of the study drug was followed by coronary arteriography, and candidates for percutaneous transluminal coronary angioplasty were randomly assigned either to undergo angioplasty on the third hospital day (n = 42) or not to undergo angioplasty during the 10-day study period (n = 43

NEJM1987

1095. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. 2956516 1987 09 21 1987 09 21 2012 11 15 0028-4793 317 10 1987 Sep 03 The New England journal of medicine N. Engl. J. Med. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. 581-8 We compared the efficacy of immediate coronary angioplasty after acute (...) myocardial infarction with that of elective angioplasty at 7 to 10 days in patients treated initially with intravenous tissue plasminogen activator. The plasminogen activator (150 mg) was administered 2.95 +/- 1.1 hours after the onset of symptoms, to 386 patients with acute myocardial infarction. Ninety minutes later, patency of the coronary artery serving the area of the infarct was demonstrated by coronary angiography in 288 patients (75 percent). Bleeding problems were frequently encountered, as evidenced

NEJM1987

1096. Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI).

Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI). 2889079 1987 11 17 1987 11 17 2015 06 16 0140-6736 2 8564 1987 Oct 17 Lancet (London, England) Lancet Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI). 871-4 (...) Long-term follow-up of 98.3% of the 11,712 patients recruited in the GISSI trial of intravenous streptokinase (SK) in acute myocardial infarction has shown persistence of the beneficial effect observed during the hospital phase. At 12 months a significant difference in mortality was seen in the whole population (17.2% in SK group versus 19.0% in controls, p = 0.008, relative risk 0.90), and in the 0-3 and 3-6 h groups (relative risks 0.89 and 0.87, respectively). For most of the other strata

Lancet1987

1097. Prospective, randomised, double-blind study of radionuclide determination of left-ventricular ejection fraction in acute myocardial infarction.

Prospective, randomised, double-blind study of radionuclide determination of left-ventricular ejection fraction in acute myocardial infarction. 2869304 1986 04 16 1986 04 16 2016 11 23 0140-6736 1 8481 1986 Mar 15 Lancet (London, England) Lancet Prospective, randomised, double-blind study of radionuclide determination of left-ventricular ejection fraction in acute myocardial infarction. 583-5 In a controlled, randomised, double-blind study to see whether knowledge of left-ventricular ejection (...) fraction (LVEF) could reduce the frequency of left-sided heart failure after acute myocardial infarction, LVEF was determined a few days before hospital discharge in a consecutive series of 60 patients. Subsequently, the patients were randomly assigned to two groups. The cardiologist responsible for their treatment was aware of the LVEF result in group I but not in group II. A month after hospital discharge there was no significant difference in the LVEF between the groups. 2 months after discharge

Lancet1986

1098. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction.

A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. 2936956 1986 04 15 1986 04 15 2016 11 23 0028-4793 314 13 1986 Mar 27 The New England journal of medicine N. Engl. J. Med. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. 812-8 We randomly assigned 56 patients who presented within 12 hours of their first symptoms of acute (...) myocardial infarction to treatment with either intracoronary streptokinase or coronary angioplasty. The mean (+/- SD) duration of symptoms (3.0 +/- 1.2 hours in the group treated with angioplasty vs. 3.6 +/- 1.8 in the group treated with streptokinase; P not significant) and time to recanalization (4.1 +/- 1.4 hours vs. 4.8 +/- 1.7 hours; P not significant) were similar in both groups. Coronary recanalization was achieved in 83 percent of the patients treated with angioplasty and in 85 percent of those treated

NEJM1986

1099. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. The I.S.A.M. Study Group.

A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. The I.S.A.M. Study Group. 2871492 1986 06 20 1986 06 20 2007 11 15 0028-4793 314 23 1986 Jun 05 The New England journal of medicine N. Engl. J. Med. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days. The I.S.A.M. Study Group. 1465-71 Within six hours after (...) the onset of symptoms of myocardial infarction, we randomly assigned 1741 patients up to 75 years of age to a one-hour intravenous infusion of 1.5 million IU of streptokinase or placebo. At 21 days mortality was 6.3 percent in the streptokinase group and 7.1 percent in the placebo group. Of those treated within three hours of the onset of symptoms, 5.2 percent died in the streptokinase group (n = 477), as compared with 6.5 percent in the placebo group (n = 463). These differences were not significant

NEJM1986

1100. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). 2868337 1986 03 20 1986 03 20 2015 06 16 0140-6736 1 8478 1986 Feb 22 Lancet (London, England) Lancet Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). 397-402 In an unblinded trial of intravenous streptokinase (...) (SK) in early acute myocardial infarction, 11 806 patients in one hundred and seventy-six coronary care units were enrolled over 17 months. Patients admitted within 12 h after the onset of symptoms and with no contraindications to SK were randomised to receive SK in addition to usual treatment and complete data were obtained in 11 712. At 21 days overall hospital mortality was 10.7% in SK recipients versus 13% in controls, an 18% reduction (p = 0.0002, relative risk 0.81). The extent

Lancet1986